Created by Lilly Oncology, PACE (Patient Access to Cancer care Excellence) is an emerging global network of collaborations between industry and other sectors intended to improve public policies that determine the accessibility, speed and value of progress against cancer. PACE exists to encourage public policies and health care decisions that speed the development of new medicines, assure cancer treatments respond to the needs and qualities of individual patients and improve patient access to the most effective cancer medicines. The PACE network includes a Global Council of internationally renowned patient advocacy, medical, policy, scientific and health care industry leaders.

What are the areas of focus for PACE? Three key areas form the pillars of PACE:

- Policy Aligned with Progress: Align the interests of all stakeholders for progress in fitting the treatment to the patient
- Patient-Centered Decisions and Care: Put patients’ interests at the heart of everything for which PACE stands
- Education and Understanding: Educate and empower stakeholders on the facts about cancer care and treatment: past, present and future

PACE will focus on the following issues:

- Helping to ensure that the voice of the patient is heard and heeded in decisions on the development, assessment, use and payment of new treatments for cancer
- Working with other stakeholders to improve the design and conduct of clinical trials
- Helping to improve patients’ access to cancer treatments that are most effective for them (the right medicine to the right patient)
- Educating on the nature of cancer, progress in fighting it, the research and development process, and ways of assessing the value of cancer treatment

Why did Lilly create PACE? We are at a pivotal point in the fight against cancer. Progress in medicine and health care has taken place through countless innovations—many of which were stepped improvements. But current economic pressures are jeopardizing this progress and placing our society’s larger advances against cancer at risk. As a leader in the oncology field, we at Lilly believe we have an obligation to advocate for patient access to the best treatments possible.
Where is PACE being implemented? PACE is a global program that is being implemented in the following six countries—France, Germany, Italy, Japan, United Kingdom and United States—and will engage key oncology stakeholders in each: patients, advocacy, payers, policymakers, providers, the public, researchers and politicians. These countries are important for their significant influence in shaping broader policy models in cancer care, but the ideas, materials and models of engagement that will be developed will be highly relevant to other countries across the world.

Is PACE the first program of its kind? There are a number of initiatives to improve the public policy and regulatory environment around oncology innovation and cancer care in Europe, Japan and the United States, and PACE will not duplicate these efforts. Instead, PACE looks to enhance the awareness and coordination between these efforts, working to fill any knowledge gaps and build awareness and momentum.

What are the key initiatives of PACE? The year 2012 was a foundational year for PACE, including:

- Establishing a global network of collaborations between industry and other sectors
- Conducting the PACE Cancer Perception Index, a public opinion survey
- Outlining a comprehensive education campaign, including a PACE-dedicated website
- Developing and implementing an advocacy training program called MEET (Medicine Evaluation Educational Training)
- Undertaking additional, country-specific initiatives

In 2013, in addition to releasing findings of the PACE Cancer Perception Index and launching the PACE website, we will issue a PACE Action Plan that will outline policy-reform initiatives and put forth steps relevant across geographies.
What is the PACE Cancer Perception Index? The PACE Cancer Perception Index, a Six-Nation Survey of Cancer Knowledge and Attitudes Among the General Population, Patients and Caregivers, gauged public knowledge and perceptions about the current state and value of cancer progress; the patient/caregiver’s role; and overall confidence in the health care system. The survey polled 4,341 individuals, including the general population (3,009), cancer patients (663) and caregivers (669), from August 28 to October 4, 2012. Survey participants were from six countries: the United States, France, Germany, Italy, Japan and the United Kingdom. For further information, please see the PACE Cancer Perception Index Fact Sheet.

What is MEET? MEET is part of the advocacy pillar of PACE, and stands for Medicine Evaluation Educational Training. It is a proprietary, multilingual, interactive one-day training workshop designed to help patient advocacy group leaders and policy level personnel understand and engage in the journey of a medicine, including: medicine discovery, the regulatory process, health technology assessment/medicine evaluation and patient interaction with the clinical trial process.

#  #  #